艾立布林对比医生选择方案治疗晚期非小细胞肺癌的随机开放多中心3期研究
这项3期研究将540例经重度预处理的晚期非小细胞肺癌患者随机分为艾立布林组(n=270)和医生选择方案组(n=270)。两组中位总生存期均为9.5个月(HR 1.16,95%CI 0.95-1.41,P=0.13),艾立布林未显示优于医生选择方案。但艾立布林在三线治疗中显示出活性。
要点
- 艾立布林组与医生选择方案组中位总生存期均为9.5个月,无显著差异
- 艾立布林组客观缓解率12%,医生选择方案组15%
- 艾立布林组周围感觉神经病变发生率16%,高于医生选择方案组的9%
核心结论
- 这项3期研究未证明艾立布林在总生存期方面优于医生选择方案,但艾立布林在非小细胞肺癌三线治疗中显示出活性。
研究设计与样本
- 随机、开放标签、多中心3期研究,纳入既往接受过≥2线治疗(包括铂类双药化疗和表皮生长因子受体酪氨酸激酶抑制剂)的晚期非小细胞肺癌患者540例,随机分为艾立布林组(n=270)和医生选择方案组(n=270)。
主要发现
- 艾立布林组与医生选择方案组中位总生存期均为9.5个月(HR 1.16;95%CI 0.95-1.41;P=0.13)。
- 艾立布林组中位无进展生存期3.0个月,医生选择方案组2.8个月(HR 1.09;95%CI 0.90-1.32;P=0.39)。
- 艾立布林组客观缓解率12%,医生选择方案组15%;临床获益率分别为57%和55%;疾病控制率分别为63%和58%。
- 最常见不良事件为中性粒细胞减少,艾立布林组所有级别发生率57%,医生选择方案组49%。
- 除周围感觉神经病变(所有级别:艾立布林组16%,医生选择方案组9%)外,其他非血液学副作用两组均可管理且相似。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Eribulin is a microtubule dynamics inhibitor with a novel mechanism of action. This phase 3 study aimed to compare overall survival (OS) in patients with heavily pretreated non-small cell lung cancer (NSCLC) receiving eribulin to treatment of physician's choice (TPC). PATIENTS AND METHODS: Patients with advanced NSCLC who had received ≥2 prior therapies, including platinum-based doublet and epidermal growth factor receptor tyrosine kinase inhibitor, were randomly assigned to receive eribulin or TPC (gemcitabine, pemetrexed, vinorelbine, docetaxel). The primary endpoint was OS. Secondary endpoints were progression-free survival and objective response rate. RESULTS: Five hundred and forty patients were randomized to either eribulin (n = 270) or TPC (n = 270). Median OS for eribulin and TPC was the same: 9.5 months [hazard ratio (HR): 1.16; 95% confidence interval: 0.95-1.41; P = 0.13]. Progression-free survival for eribulin and TPC was 3.0 and 2.8 months, respectively (HR: 1.09; 95% confidence interval: 0.90-1.32; P = 0.39). The objective response rate was 12% for eribulin and 15% for TPC. Clinical benefit rate (eribulin, 57%; TPC, 55%) and disease control rate (eribulin, 63%; TPC, 58%) were similar between treatment arms. The most common adverse event was neutropenia, which occurred in 57% of eribulin patients and 49% of TPC patients at all grades. Other non-hematologic side-effects were manageable and similar in both groups except for peripheral sensory neuropathy (all grades; eribulin, 16%; TPC, 9%). CONCLUSION: This phase 3 study did not demonstrate superiority of eribulin over TPC with regard to overall survival. However, eribulin does show activity in the third-line setting for NSCLC. TRIAL REGISTRATION ID: www.ClinicalTrials.gov; NCT01454934.
引用
- Katakami N, Felip E, Spigel DR, et al. A randomized, open-label, multicenter, phase 3 study to compare the efficacy and safety of eribulin to treatment of physician's choice in patients with advanced non-small cell lung cancer. Ann Oncol. 2017. PMID: 28911085. doi:10.1093/annonc/mdx284
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。